Marc M. P. de Garidel

European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

Despite recent advances in diagnostics, imaging, medical devices and surgical procedures, there has been limited progress in pharmacological treatments for a number of neurological and neuro-oncological pathologies. For pathologies like central and peripheral nervous system injuries, degenerative diseases and tumours of the nervous system, the unmet medical needs are countless and there is growing expectation from the medical community, the patients and their relatives to benefit from clinically proven solutions in the future that will save and/or improve the lives of many. The limited efficacy of approved therapies for some of these pathologies and the orphan nature of others has prompted the urgent need for new researches and therapeutic strategies. At Pharmaxon, as the pioneers of a novel pharmacological approach based on cell mobility modulation, the firm is developing the future 'control keys' for improving the nervous system's endogenous regeneration, modulating neuronal networks plasticity, and inhibiting the processes which underlie tumour cell proliferation and migration. This is obtained by modulating the activity of specific adhesion molecules implicated in cell migration, cell adhesion and cell growth. Based on such a targeted strategy, Pharmaxon is opening up new avenues for the medical management of some serious, poorly-treated, neurology and neuro-oncology pathologies. To date, this has led to three R&D programs which have reached proof-of-principle, confirming the therapeutic potential of this innovative approach, in clinic stage by 2008.

Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland.

PX Therapeutics SA manufactures and develops recombinant proteins and monoclonal antibodies. Its services include protein engineering, optimization of drug candidates, humanization of antibodies, and production and release of GMP batches for clinical studies. The firm specializes in the field of in-vivo and in-vitro diagnostics, industrial enzymes, and ancillary products. The company was founded by Tristan Rousselle and Nicolas Mouz in November 2000 and is headquartered in Grenoble, France.

The Innovative Medicines Initiative is a public-private partnership that aims to accelerate the development of better and safer medicines for patients. The private company is based in Brussels, Belgium and has subsidiaries in Sweden. The Programme Office, led by the Executive Director, manages the day-to-day operations of the initiative. The initiative recognizes the importance of communication and provides accessible tools generated by their projects to help scientists in their research efforts. The Belgian company was founded by J. Kenneth Charles Knowles.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA.

CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA.

Claris Biotherapeutics, Inc. engages in the manufacturing of drugs. The company was founded in 2018 and is headquartered in Jersey City, NJ.